Kalocyte Closes Investment From New York Blood Center
Jul 20, 2022•about 3 years ago
BaltimoreSportsHealth Care
Description
KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMerTM, today announced it has closed an investment from New York Blood Center, Inc. (NYBC).
Company Information
Company
KaloCyte
Location
Baltimore, Maryland, United States
About
KaloCyte is redefining future emergency treatment for victims of traumatic blood loss with its first-in-class product ErythroMer, a dried red blood cell substitute that is easily transported and rapidly administered for when perishable donor blood is unavailable.
Baltimore